104884
N-[3-（三甲氧基硅基）丙基]乙二胺
97%
别名:
3-(2-氨基乙基氨基)丙基三甲氧基硅烷, Dow Corning® 产品 Z-6094, N-(2-氨乙基)-3-(三甲氧基硅基)丙胺
登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
(CH3O)3Si(CH2)3NHCH2CH2NH2
化学文摘社编号:
分子量:
222.36
UNSPSC Code:
12352103
NACRES:
NA.22
PubChem Substance ID:
EC Number:
217-164-6
Beilstein/REAXYS Number:
636230
MDL number:
产品名称
N-[3-（三甲氧基硅基）丙基]乙二胺, 97%
InChI key
PHQOGHDTIVQXHL-UHFFFAOYSA-N
InChI
1S/C8H22N2O3Si/c1-11-14(12-2,13-3)8-4-6-10-7-5-9/h10H,4-9H2,1-3H3
SMILES string
CO[Si](CCCNCCN)(OC)OC
assay
97%
form
liquid
refractive index
n20/D 1.444 (lit.)
bp
146 °C/15 mmHg (lit.)
density
1.028 g/mL at 25 °C (lit.)
functional group
amine
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
N-[3-（三甲氧基甲硅烷基）丙基]乙二胺也已用作有机配体，从而用于硅胶的表面改性以吸收重金属离子。它可与氟化碳纳米管（F-CNT）反应形成氨基烷基烷氧基硅烷官能化的碳纳米管。
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Inhalation - Eye Dam. 1 - Skin Sens. 1B - STOT RE 2 Inhalation
target_organs
respiratory tract irritation
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
276.8 °F - closed cup
flash_point_c
136 °C - closed cup
ppe
Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter
Adsorption of Cu (II) and Pb (II) onto a grafted silica: isotherms and kinetic models.
Chiron N, at. al.
Water Research, 37(13), 3079-3086 (2003)
Functionalization of single-walled carbon nanotubes with N-[3-(trimethoxysilyl) propyl] ethylenediamine and its cobalt complex.
Oki A
Journal of Physics and Chemistry of Solids, 69(5-6), 1194-1198 (2008)
Adsorption of heavy metal cations by organic ligands grafted on porous materials.
Vasiliev A
Microporous and Mesoporous Materials : The Official Journal of the International Zeolite Association, 118(1-3), 251-257 (2009)
Terry O Collier et al.
Journal of biomedical materials research. Part A, 69(4), 644-650 (2004-05-27)
The ability of monocytes to adhere, differentiate into macrophages, and fuse to form foreign body giant cells (FBGCs) on an implanted material surface is a critical step toward biomaterial degradation. Novel homogeneous surfaces were utilized to mediate adhesion. These surfaces
J G Horswill et al.
British journal of pharmacology, 152(5), 805-814 (2007-06-27)
Rimonabant (Acomplia, SR141716A), a cannabinoid CB1 receptor inverse agonist, has recently been approved for the treatment of obesity. There are, however, concerns regarding its side effect profile. Developing a CB1 antagonist with a different pharmacological mechanism may lead to a
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持